These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 27956805

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients.
    Wang CT, Zhang YF, Sun BH, Dai Y, Zhu HL, Xu YH, Lu MJ, Yang DL, Li X, Zhang ZH.
    World J Gastroenterol; 2015 May 14; 21(18):5668-76. PubMed ID: 25987794
    [Abstract] [Full Text] [Related]

  • 3. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
    Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL.
    Gastroenterology; 2012 Mar 14; 142(3):513-520.e1. PubMed ID: 22108195
    [Abstract] [Full Text] [Related]

  • 4. Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population.
    Wang H, Wu H, Bao S, Xiang X, Zhao G, Liu K, Li F, Xu Y, An B, Zhou H, Lu J, Xie Q.
    Infect Genet Evol; 2015 Apr 14; 31():161-8. PubMed ID: 25640825
    [Abstract] [Full Text] [Related]

  • 5. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
    Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN.
    J Gastroenterol Hepatol; 2011 Mar 14; 26(3):461-8. PubMed ID: 21332543
    [Abstract] [Full Text] [Related]

  • 6. Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus.
    Domagalski K, Pawłowska M, Zaleśna A, Pilarczyk M, Rajewski P, Halota W, Tretyn A.
    World J Gastroenterol; 2016 Nov 07; 22(41):9186-9195. PubMed ID: 27895405
    [Abstract] [Full Text] [Related]

  • 7. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL.
    Gastroenterology; 2009 Dec 07; 137(6):2002-9. PubMed ID: 19737568
    [Abstract] [Full Text] [Related]

  • 8. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH.
    Antivir Ther; 2011 Dec 07; 16(5):629-37. PubMed ID: 21817184
    [Abstract] [Full Text] [Related]

  • 9. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY.
    World J Gastroenterol; 2015 Nov 21; 21(43):12421-9. PubMed ID: 26604649
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.
    Yang YF, Zhao W, Zhong YD, Yang YJ, Shen L, Zhang N, Huang P.
    Antiviral Res; 2008 Feb 21; 77(2):136-41. PubMed ID: 18078676
    [Abstract] [Full Text] [Related]

  • 11. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct 21; 20(10):737-41. PubMed ID: 23207332
    [Abstract] [Full Text] [Related]

  • 12. [Study on the relationship between hepatitis B virus genotypes and the effect of polyethylene glycol-interferon-alpha therapy on HBeAg-positive chronic hepatitis B].
    Gao GS, Xu XZ, Hu YR, Yan HD.
    Zhonghua Nei Ke Za Zhi; 2013 Dec 21; 52(12):1009-12. PubMed ID: 24503396
    [Abstract] [Full Text] [Related]

  • 13. Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Jiang DK, Wu X, Qian J, Ma XP, Yang J, Li Z, Wang R, Sun L, Liu F, Zhang P, Zhu X, Wu J, Chen K, Conran C, Zheng SL, Lu D, Yu L, Liu Y, Xu J.
    Hepatology; 2016 Apr 21; 63(4):1102-11. PubMed ID: 26704347
    [Abstract] [Full Text] [Related]

  • 14. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB, Golge N, Akin MS.
    Eur J Gastroenterol Hepatol; 2013 Nov 21; 25(11):1312-6. PubMed ID: 23652913
    [Abstract] [Full Text] [Related]

  • 15. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.
    Zhang Q, Lapalus M, Asselah T, Laouénan C, Moucari R, Martinot-Peignoux M, Bieche I, Estrabaud E, De Muynck S, Boyer N, Bedossa P, Vidaud M, Marcellin P, Lada O.
    J Viral Hepat; 2014 Jul 21; 21(7):525-32. PubMed ID: 24118626
    [Abstract] [Full Text] [Related]

  • 16. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, Beld M, Reesink H.
    J Gastroenterol Hepatol; 2011 Oct 21; 26(10):1527-35. PubMed ID: 21557773
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
    Caruntu FA, Streinu-Cercel A, Gheorghe LS, Grigorescu M, Sporea I, Stanciu C, Andronescu D, Voinea F, Diculescu M, Oproiu A, Voiosu R.
    J Gastrointestin Liver Dis; 2009 Dec 21; 18(4):425-31. PubMed ID: 20076814
    [Abstract] [Full Text] [Related]

  • 18. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.
    Am J Gastroenterol; 2005 Nov 21; 100(11):2463-71. PubMed ID: 16279901
    [Abstract] [Full Text] [Related]

  • 19. Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon.
    Boglione L, Cusato J, De Nicolò A, Cariti G, Di Perri G, D'Avolio A.
    J Viral Hepat; 2015 Mar 21; 22(3):318-27. PubMed ID: 25060765
    [Abstract] [Full Text] [Related]

  • 20. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan QQ, Yu AS, Mohammed W, Velasco A, LeDuc VH, Nguyen N, Han SB, Chang M, Bae HS, Cho YW, Tong MJ, Cooper SL.
    Dig Dis Sci; 2015 Nov 21; 60(11):3465-72. PubMed ID: 26138653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.